Last updated: 2026-10-13 23:14:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
SpyGlass Pharma, Inc. (SGP) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $24.04, with a market capitalisation of $833.52M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $17.06 to $32.44. This page covers its latest market performance, valuation, price trends and company information.
$833.52M | |
$24.53 | |
$35.15 | |
$11.97 | |
$24.86 | |
55.24K | |
104.78K | |
-- | |
$32.44 | |
$17.06 | |
-- | |
-- |
SpyGlass Pharma, Inc. (SGP) is trading at $24.04 in after-hours trading as of 2026-10-13 19:57:26, down 3.30% ($0.82) from the regular-session close of $24.86.
After-hours trading shows how investors are pricing SGP after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, SpyGlass Pharma, Inc. (SGP) moved from $24.92 to $24.04, representing a decline of 3.53% ($0.88).
The stock traded between $23.29 and $27.11 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 88.32 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 45.4%
SGP is currently trading at $24.04, placing it 45.4% of the way from its 52-week low of $17.06 to its 52-week high of $32.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 65 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of SpyGlass Pharma, Inc. (SGP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.